Sign inJoin waitlistJoin the waitlist

Siddharth Sheth

Tenure-Track Assistant Professor of Medicine in the Division of Medical Oncology · University of North Carolina (UNC) at Chapel Hill

Credentials: · · · · ·

History

University of North Carolina (UNC) at Chapel Hill
Present
University of North Carolina (UNC) at Chapel Hill
Present

University of North Carolina at Chapel Hill
AstraZeneca
University of Pittsburgh Medical Center
Lake Erie College of Medicine
2016
University of North Carolina at Chapel Hill

Research

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Clinical Cancer Research · 2020 · 112 citations
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Review · Journal of Clinical Oncology · 2023 · 88 citations
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials
Systematic review or meta-analysis · BMC Infectious Diseases · 2010 · First of 2 authors · Corresponding · 41 citations

Trevor Hackman
26 papers
NL
Nicholas Lenze
19 papers · 6 as a resident
Wendell Yarbrough
19 papers
DF
Douglas Farquhar
15 papers · 15 as a resident
Jose Zevallos
15 papers
JT
Jason Tasoulas
14 papers · 9 as a resident
AZ
Adam Zanation
13 papers
MW
Mark Weissler
12 papers
Bhishamjit Chera
11 papers
Samip Patel
11 papers
Jared Weiss
10 papers
Neil Hayes
9 papers

Grants

NCI Research Specialist (Clinician Scientist) R50 Award - Siddharth Sheth
National Cancer Institute · R50
Contact PI · $163.1K · Univ of North Carolina Chapel Hill
2026–2031

Clinical trials

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2030
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
Principal investigator · Not yet recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2026–2028
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Principal investigator · Recruiting · Phase 1
UNC Lineberger Comprehensive Cancer Center
2025–2028
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029